SAN DIEGO--(BUSINESS WIRE)--Jul. 30, 2025-- DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2025.

Second Quarter 2025 Financial Highlights:

• Revenue grew 15% year-over-year to $1.157 billion on a reported basis and 15% year-over-year on an organic¹ basis.
• U.S. revenue grew 15% and international revenue grew 16% on a reported basis and 14% on an organic¹ basis, all on a year-over-year basis.
• GAAP operating income of $212.6 million or 18.4% of revenue, an increase of 270 basis points compared to the second quarter of 2024. Non-GAAP operating income* of$221.8 million or 19.2% of reported revenue, a decrease of 30 basis points compared to the second quarter of 2024.

Second Quarter 2025 Strategic Highlights:

• Received FDA clearance for Dexcom G7 15 Day CGM System.
• Showcased extensive clinical evidence at the American Diabetes Association’s 85th Scientific Sessions, including new data demonstrating the benefits of Dexcom CGM usage for gestational diabetes and for people with type 2 diabetes who are not using insulin.
• Launched AI-based Smart Food Logging feature, simplifying the process of meal logging for our customers.
• Enhanced the Stelo customer experience with new software features, broader distribution, and digital health partnerships.

“During the quarter, Dexcom delivered strong revenue results, presented compelling clinical data at ADA, and further advocated for expanded coverage in key growth markets,” said Kevin Sayer, Dexcom’s chairman and CEO. “In the second half of 2025, we look forward to continuing our commercial momentum while advancing our product portfolio with the highly-anticipated launch of our Dexcom G7 15 Day System.”

2025 Annual Guidance

Dexcom is raising fiscal year 2025 guidance for Revenue, and reiterating guidance for Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin at the following levels:

• Revenue of $4.600 - $4.625 billion (14-15% growth)
• Non-GAAP Gross Profit Margin of approximately 62%
• Non-GAAP Operating Margin of approximately 21%
• Adjusted EBITDA Margin of approximately 30%

CEO Succession Effective January 1, 2026

Dexcom today also announced the promotion of Jake Leach to CEO and to the Dexcom Board of Directors, effective January 1, 2026. Current CEO Kevin Sayer will continue to work closely with Jake during the transition period and will remain executive chairman of the board of directors at the point of transition.

“Today’s announcement of Jake’s transition to the role of chief executive officer reflects the Board’s comprehensive succession planning and their confidence in Jake’s leadership throughout his tenure. We are confident that he is the right leader to build on Dexcom’s momentum and extend the company’s growth well into the future,” said Kevin Sayer.

“I am humbled and excited to transition into the CEO role at this critical time in Dexcom’s history,” said Jake Leach. “I look forward to leading our incredible teams as we advance access to our technology to more people around the world, empowering better metabolic health for our customers and creating value for our stakeholders.”

Mr. Leach has helped steer the company’s biosensing platforms since the launch of its first commercial system. He has held roles of increasing responsibility across his 21-year tenure with the company. He served as executive vice president and chief technology officer from 2018 through 2022, transitioning to executive vice president and chief operating officer in late 2022. In May 2025, he was promoted to the expanded role of president and chief operating officer, assuming the additional responsibility of oversight for the company’s strategy and corporate development efforts.

Second Quarter 2025 Financial Results

Revenue: In the second quarter of 2025, worldwide revenue grew 15% to $1.157 billion on a reported basis, up from $1.004 billion in the second quarter of 2024.

Gross Profit: GAAP gross profit totaled $688.8 million or 59.5% of revenue for the second quarter of 2025, compared to $626.7 million or 62.4% of revenue in the second quarter of 2024.

Non-GAAP gross profit* totaled $695.9 million or 60.1% of reported revenue for the second quarter of 2025, compared to $638.1 million or 63.5% of reported revenue in the second quarter of 2024.

Operating Income: GAAP operating income for the second quarter of 2025 was $212.6 million or 18.4% of revenue, compared to GAAP operating income of $158.0 million or 15.7% of revenue for the second quarter of 2024.

Non-GAAP operating income* for the second quarter of 2025 was $221.8 million or 19.2% of reported revenue, compared to non-GAAP operating income of $195.4 million or 19.5% of reported revenue for the second quarter of 2024.

Net Income and Diluted Net Income Per Share: GAAP net income was $179.8 million, or $0.45 per diluted share, for the second quarter of 2025, compared to GAAP net income of $143.5 million, or $0.35 per diluted share, for the second quarter of 2024.

Non-GAAP net income* was $192.8 million, or $0.48 per diluted share, for the second quarter of 2025, compared to non-GAAP net income of $174.3 million, or $0.43 per diluted share, for the second quarter of 2024. The second quarter 2025 non-GAAP net income excludes $7.9 million of amortization of intangible assets, $1.1 million of business transition and other significant items, $0.2 million of intellectual property litigation costs, $0.4 million of loss from equity investments, and $3.4 million of tax adjustments.

Cash and Liquidity: As of June 30, 2025, Dexcom held $2.93 billion in cash, cash equivalents and marketable securities and our revolving credit facility remains undrawn. The cash balance represents significant financial and strategic flexibility as Dexcom continues to expand production capacity and explore new market opportunities.

* See Table E below for a reconciliation of these GAAP and non-GAAP financial measures.

Conference Call

Management will hold a conference call today starting at 4:30 p.m. (Eastern Time). The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com by navigating to “Events and Presentations,” and will be archived for future reference. To listen to the conference call, please dial (888) 414-4585 (U.S./Canada) or (646) 960-0331 (International) and use the confirmation ID “9430114” approximately five minutes prior to the start time.

Statement Regarding Use of Non-GAAP Financial Measures

This press release and the accompanying tables include non-GAAP financial measures. For a description of these non-GAAP financial measures, including the reasons management uses each measure, and reconciliations of these non-GAAP financial measures to the most directly comparable financial measures prepared in accordance with generally accepted accounting principles in the United States (GAAP), please see the section titled “About Non-GAAP Financial Measures” below as well as the related Table E. We have not reconciled our organic revenue growth, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin estimates for fiscal year 2025 because certain items that impact these figures are uncertain or out of our control and cannot be reasonably predicted. Accordingly, reconciliations of our organic revenue growth, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin and Adjusted EBITDA Margin estimates are not available without unreasonable effort.

About DexCom, Inc.

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com.

Category: IR

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements that are not purely historical regarding Dexcom’s or its management’s intentions, beliefs, expectations and strategies for the future, including those related to Dexcom’s future operating results and financial position, including estimated Revenue, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin for fiscal year 2025, and expected growth rates as compared to the year ended December 31, 2024; future expenses and investments; and potential business plans and opportunities. All forward-looking statements included in this press release are made as of the date of this press release, based on information currently available to Dexcom as of the date hereof. Forward-looking statements deal with future events and are therefore subject to various risks and uncertainties. Actual results could differ materially from those anticipated in these forward-looking statements. The risks and uncertainties that may cause actual results to differ materially from Dexcom’s current expectations are more fully described in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Dexcom’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings filed with the Securities and Exchange Commission. Except as required by law, Dexcom assumes no obligation to update any such forward-looking statement after the date of this communication or to conform these forward-looking statements to actual results.

ABOUT NON-GAAP FINANCIAL MEASURES

The accompanying press release dated July 30, 2025 contains non-GAAP financial measures. These non-GAAP financial measures include organic revenue, non-GAAP gross profit margin, non-GAAP operating income, non-GAAP operating margin, non-GAAP net income, non-GAAP diluted net income per share, and non-GAAP diluted weighted average shares outstanding, as well as Adjusted EBITDA.

We report non-GAAP financial measures in addition to, and not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP. We use these non-GAAP financial measures for financial and operational decision making and period-to-period comparisons. We believe that these non-GAAP financial measures provide useful information about operating results, enhance the overall understanding of our operating performance and future prospects, and allow for greater transparency with respect to key metrics used by senior management in our financial and operational decision making. Our non-GAAP financial measures exclude amounts that we do not consider part of ongoing operating results when planning and forecasting and when assessing the performance of the organization and our senior management. While we compute non-GAAP financial measures using a consistent method from quarter to quarter and year to year, we may consider whether other significant items that arise in the future should be excluded from our non-GAAP financial measures.

These non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles, differ from GAAP measures with the same names, and may differ from non-GAAP financial measures with the same or similar names that are used by other companies.

We believe that non-GAAP measures have limitations in that they do not reflect all of the amounts associated with our results of operations as determined in accordance with GAAP and that these financial measures should only be used to evaluate our results of operations in conjunction with the corresponding GAAP financial measures. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand our business.

Management believes organic revenue is a meaningful metric to investors as it provides a more consistent comparison of Dexcom’s revenue to prior periods as well as to industry peers. We exclude the following items from organic revenue:

• The effect of non-CGM revenue acquired or divested in the trailing twelve months; and
• The effect of foreign currency fluctuations

Management believes that the presentation of operating results that exclude these items provides useful supplemental information to investors and facilitates the analysis of our core operating results and comparison of operating results across reporting periods. Management believes that this supplemental non-GAAP information is therefore useful to investors in analyzing and assessing our past and future operating performance.

Table E reconciles the non-GAAP financial measures included in this press release to the most directly comparable financial measures prepared in accordance with GAAP.

Our policy is to exclude the following items from non-GAAP financial measures for non-GAAP gross profit, non-GAAP operating income, non-GAAP operating margin, non-GAAP net income, and non-GAAP diluted net income per share:

• Amortization of acquired intangible assets;
• Business transition and related costs associated with acquisition and divestiture, integration and business transition activities, including severance, relocation, consulting, leasehold exit costs, third-party merger and acquisition costs, and other non-recurring significant items;
• Credits related to the employment of personnel during the COVID-19 pandemic;
• Income or loss from equity investments;
• Third-party intellectual property litigation costs in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc.;
• Litigation settlement costs;
• Gain or loss on extinguishment of debt; and
• Adjustments related to taxes for the excluded items above, as well as excess benefits or tax deficiencies from share-based compensation, and the quarterly impact of other discrete items

Adjusted EBITDA excludes non-cash operating charges for share-based compensation, depreciation and amortization as well as non-operating items such as interest income, interest expense, gain or loss on extinguishment of debt, income or loss from equity investments, and income tax expense or benefit. For the reasons explained above, Adjusted EBITDA also excludes business transition and other significant items, COVID-19 credits, litigation settlement costs, and intellectual property litigation costs.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250730050482/en/

INVESTOR RELATIONS CONTACT:
Sean Christensen
Vice President - Finance and Investor Relations
investor-relations@dexcom.com
(858) 203-6657

MEDIA CONTACT:
James McIntosh
(619) 884-2118

Source: DexCom, Inc.